pan pim kinase inhibitors pim447 (MedChemExpress)
Structured Review

Pan Pim Kinase Inhibitors Pim447, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pim+kinase+inhibitors/pmc12074636-274-28-48?v=MedChemExpress
Average 93 stars, based on 7 article reviews
Images
1) Product Images from "PIM kinase control of CD8 T cell protein synthesis and cell trafficking"
Article Title: PIM kinase control of CD8 T cell protein synthesis and cell trafficking
Journal: eLife
doi: 10.7554/eLife.98622
Figure Legend Snippet: Single-cell suspension from P14 TCR-transgenic mouse lymph nodes were activated with gp33 peptide (100 ng/mL), IL-2 (20 ng/mL), and IL-12 (2 ng/mL) for 2 days, then split daily into fresh media containing IL-2 (20 ng/mL). On day 5 of culture IL-2 expanded CTL were treated with pan-PIM kinase inhibitors PIM447 (5 µM) or AZD1208 (10 µM), or DMSO vehicle control for 24 hr and harvested on day 6 of culture to measure ( A ) Cell number ( B ) FSC-A SSC-A. Proteome analysis was also performed on inhibitor-treated CTL to measure ( C ) protein content, ( D ) protein expression of SCD1-3, SLC2A1, SLC2A3, GZMB, or ( F ) PDCD4. ( E ) Day 6 IL-2 expanded CTL from WT (C57BL/6) mice were treated for 24 hr with PIM447 or AZD1208 (both 1 µM) and GZMB expression was measured by flow cytometry. Symbols show biological replicates. Error bars show mean ± S.D. Data are representative of ( E ) n=2 biological replicates collected across at least two independent experiments. Proteomics analysis was performed on biological triplicates, with ( A, B ) collected in parallel with proteomics analysis. * q<0.05. Figure 4—figure supplement 2—source data 1. Raw values plotted in .
Techniques Used: Suspension, Transgenic Assay, Control, Expressing, Flow Cytometry
Figure Legend Snippet: RNAseq analysis was performed in day 6 IL-2 expanded WT and Pim dKO CD8 T cells which were collected in parallel with proteomics analysis described in . ( A ) Volcano plot of RNAseq data, differentially expressed mRNA (FC >1.5, q<0.05) are highlighted in red. ( B ) Volcano plot of RNAseq data, Granzymes C-K, perforin, Pdcd4 and Sell are highlighted in red. ( C ) Heatmap of mRNA expression (TPM) for granzymes, perforin and effector cytokines. Bar chart of mRNA expression (TPM) of ( D ) Granzymes A and B ( E ) Glucose transporters Slc2a1 and Slc2a3. ( F, G ) Fold change of PimdKO/WT protein from proteomics analysis described in vs mRNA ( F ) highlighting in red proteins that are differentially expressed (FC >1.5, q<0.05) where mRNA is not substantially different (FC <1.2) and ( G ) highlighting in red protein and mRNA that are both differentially expressed (FC >1.5, q<0.05). ( H ) Estimated cytosolic ribosome content per cell (left), % ribosome of total cellular protein content (right). ( I ) Estimated protein copy number per cell of translation repressor PDCD4. ( J ) PDCD4 expression measured by flow cytometry on day 3 and 6 in IL-2 expanded WT vs Pim dKO CD8 T cells. ( K ) Estimated protein copy number per cell of EIF4A1. ( L ) Adjusted ratio of PDCD4: EIF4A1 (assuming 1 PDCD4 binds 2 x EIF4A1) in WT and Pim dKO proteomes. ( M ) Protein synthesis measured by OPP incorporation in day 6 IL-2-expanded WT CTL treated for 24 hours with pan PIM kinase inhibitors PIM447 (5 µM) or AZD1208 (10 µM). 30-min cycloheximide (100 µg/mL) treatment gives no protein synthesis background control. Symbols in bar charts show biological replicates: error bars show mean ± S.D. Data are representative of ( M ) n=2 biological replicates collected over two independent experiments, ( J ) n=2 biological replicates. Quantitative proteomics and RNAseq were performed on biological triplicates. * indicates q<0.05, fold-change (FC) shown on graph when q<0.05. Figure 5—source data 1. Raw values plotted in .
Techniques Used: Expressing, Flow Cytometry, Control, Quantitative Proteomics
